The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort

Gómez-Iturriaga, A.; Cabeza, Alejandro Isidoro Pérez; Pastor, Jorge; Jové, Josep; Casaña, M.; Caamaño, A. Gómez; Mengual, J.; Henrı́quez, I.; Muñoz, J.; Hervás, A.; Segundo, Carmen González San

doi:10.1007/s12094-016-1481-5

Cited by 3 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 98%

“…Tai et al (23) revealed that men with only one risk factor had a 5-year BCR-free survival rate of 76.9%, compared with 34.6% in men with ≥2 risk factors. Gomez- Iturriaga et al (24) identified 1,341 extreme-risk PCa (T3b-4, GS 9-10 or PSA >50 ng/mL; or patients with two or more high-risk factors: T2c-3a, GS 8 and PSA >20 ng/mL), and the 10-year BCR, clinical-free survival, PCSS and OS were 57.0%, 78.9%, 93.6%, and 71.3%, respectively. The PCSS curve of seven groups showed that men with one risk factor of T3-4 had the best survival, and men with one risk factor of PSA >20 ng/mL had similar survival outcomes with those with two high-risk factors of T3-4 and PSA >20 ng/mL.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognosis of men with high-risk prostate cancer stratified by risk factors: a population-based retrospective cohort study

Song¹,

Wang²,

Shu³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: The aim was to evaluate the prognosis of men with all possible high-risk prostate cancers (PCa) stratified by risk factors.Methods: Within the Surveillance, Epidemiology and End Results (SEER) database from 2004 to 2015, men with non-metastasis high-risk PCa were identified. Kaplan-Meier analysis and Cox regressions were adopted to evaluate the overall survival (OS) and prostate cancer-specific survival (PCSS). Nomograms were conducted to build a predictive model. Concordance index (C-index) and calibration curves were used to validate the model.Results: A total of 151,799 patients were included. Seven risk groups were divided including one highrisk factor of T3-4 (A1), prostate-specific antigen (PSA) >20 ng/mL (A2), and Gleason score (GS) 8-10, two high-risk factors of T3-4 PSA >20 ng/mL (B1), T3-4 GS 8-10 (B2), PSA >20 ng/mL GS 8-10 (B3), and three high-risk factors of T3-4 PSA >20 ng/mL GS 8-10 (C). The survival curves of PCSS showed that A1 was the best among all groups. A2, A3 and B1 had similar results and were all better than B2 [with A2 as

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Prognosis of men with high-risk prostate cancer stratified by risk factors: a population-based retrospective cohort study

Song¹,

Wang²,

Shu³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Gomez-Iturriaga et al [23] identi ed 1341 extreme-risk PCa (T3b-4, GS 9-10 or PSA > 50 ng/ml; or patients with 2 or more high-risk factors: T2c-3a, GS 8 and PSA > 20 ng/ml), and the 10-year BCR, clinical-free survival, PCSS and OS were 57.0%, 78.9%, 93.6%, and 71.3%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Prognosis of men with high-risk prostate cancer stratified by risk factors: A population-based retrospective cohort study

Song

Dong

2020

Preprint

View full text Add to dashboard Cite

Objective: To evaluate the prognosis of men with high-risk prostate cancers (PCa) stratified by high-risk factors.Methods: Men with localized high-risk PCa were identified from 2004 to 2015. Kaplan–Meier analysis and Cox regressions were adopted to evaluate prostate cancer-specific survival (PCSS). Results: A total of 151,799 patients were included. Seven risk groups were divided including one high-risk factor of T3-4 (A1), prostate-specific antigen (PSA) >20 ng/ml (A2), and Gleason score (GS) 8-10, two high-risk factors of T3-4 PSA>20 ng/ml (B1), T3-4 GS 8-10 (B2), PSA>20 ng/ml GS 8-10 (B3), and three high-risk factors of T3-4 PSA>20 ng/ml and GS 8-10 (C). The PCSS results showed that A1 was the best among all groups. A2, A3 and B1 were similar and were all better than B2. No significant difference existed between B3 and C and these two were the worst in prognosis. The 10-year PCSS rates of A1, A2, A3, B1, B2, B3, and C group were 95.8%, 86.9%, 86.1%, 86.9%, 80.8%, 64.7% and 65.6%, respectively. Three simplified groups were divided including a good prognosis group (A1), an intermediate prognosis group (A2, A3, B1 and B2), and a poor prognosis group (B3 and C). The 10-year PCSS rate of three groups were 95.8% vs 85.1% vs 66.5%. Compared to the good prognosis group, the HR of the intermediate and poor prognosis group were 4.21(3.96~4.48) and 11.36 (10.59~12.19). A nomogram was built based on these factors. The C-index of the nomogram was 0.772, indicating a good accuracy of the model. Conclusions: We regrouped men with high-risk PCa according to their prognosis. PCa with three high-risk factors was not more aggressive than that with two of GS 8-10 and PSA >20 ng/ml.

show abstract

“…Although this trend was not significant and in contrast to previous controversial results, 4,8,9 if confirmed, it suggests that the CCP score may help stratify better highrisk localized prostate cancers into "favourable high-risk" and "unfavourable high-risk" groups, as it is been suggested from clinical factors in a previous study. 17 In addition to this, early failures (before 5 years) are more indicative of very aggressive disease and, therefore, clinically relevant due to higher possibility of these pts for disease specific mortality. 9,14 If true, then a high CCP score at diagnosis predicts micrometastatic disease, and these events would indicate the need for more aggressive treatment initially (i.e.…”

Section: Discussionmentioning

confidence: 99%

Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy

López

Parada

Gallardo

et al. 2017

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

a b s t r a c tObjectives: Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness.The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT).Methods: CCP score and Ki-67 were derived retrospectively from pre-treatment paraffinembedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006.

show abstract

The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort

Abstract: Patients presenting at diagnosis with two extreme-risk criteria have almost fourfold higher risk for prostate cancer mortality. Such patients should be considered for more aggressive multimodal treatments.

Cited by 3 publications

References 22 publications

Prognosis of men with high-risk prostate cancer stratified by risk factors: a population-based retrospective cohort study

Prognosis of men with high-risk prostate cancer stratified by risk factors: a population-based retrospective cohort study

Prognosis of men with high-risk prostate cancer stratified by risk factors: A population-based retrospective cohort study

Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy

Contact Info

Product

Resources

About